Citations

Showing 10 of 108104 citations.

Red blood cell exchange in patients with sickle cell disease—indications and management: a review and consensus report by the therapeutic apheresis subsection of the AABB
Biller, Elizabeth, Zhao, Yong, Berg, Mary , Boggio, Lisa , Fang, Deanna C., Koepsell, Scott A. , Music‐Aplenc, Lejla, Treml, Angela , Weiss, John, Wool, Geoffrey D. , Baron, Beverly W. , Baron, Beverly W , Wool, Geoffrey , Capocelli, Kelley E. , Music-Aplenc, Lejla, Pham, Huy P.

Mayo Clinic

Transfusion | September 10, 2018 | Volume: 58 | Issue: 8 | Pages: 1965-1972

10.1111/trf.14806 | PMID 30198607 Get It

BACKGROUNDA prior practice survey revealed variations in the management of patients with sickle cell disease (SCD) and stressed the need for comprehensive guidelines. Here we discuss: 1) common indications for red blood cell exchange (RCE), 2) options for access, 3) how to prepare the red blood cells (RBCs) to be used for RCE, 4) target hemoglobin (Hb) and/or hematocrit (Hct) and HbS level, 5) RBC depletion/RCE, and 6) some complications that may ensue.STUDY DESIGN AND METHODSFifteen physicians actively practicing apheresis from 14 institutions representing different areas within the United States discussed how they manage RCE for patients with SCD.RESULTSSimple transfusion is recommended to treat symptomatic anemia with Hb level of less than 9 g/dL. RCE is indicated to prevent or treat complications arising from the presence of HbS. The most important goals are reduction of HbS while also preventing hyperviscosity. The usual goals are a target HbS level of not more than 30% and Hct level of less than 30%.CONCLUSIONAlthough a consensus as to protocol details may not be possible, there are areas of agreement in the management of these patients, for example, that it is optimal to avoid hyperviscosity and iron overload, that a target Hb S level in the range of 30% is generally desirable, and that RCE as an acute treatment for pain crisis in the absence of other acute or chronic conditions is ordinarily discouraged.
The mRECIST Classification Provides Insight into Tumor Biology for Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation
Lee, David D. , Mehta, Neil , Musto, Kaitlyn R., Yao, Francis Y. , Harnois, Denise M. , Mehta, Neil , Lee, David D , Samoylova, Mariya L. , Roberts, John P.

Mayo Clinic

Liver Transplantation | September 10, 2018 | Volume: 25 | Issue: 2 | Pages: 228-241

10.1002/lt.25333 | PMID 30198150 Get It

With recent changes in United Network for Organ Sharing policy, patients in the United States with hepatocellular carcinoma (HCC) are likely to spend more time on the liver transplantation (LT) waiting list. The increasing wait time will allow for an opportunity to assess tumor biology prior to LT. Modified Response Evaluation Criteria in Solid Tumors (mRECIST) paradigm provides such a framework for this assessment, and yet little is understood of its utility as it would apply for patients listed for LT in the United States. Through a collaboration between the University of California, San Francisco, and the Mayo Clinic, Jacksonville, Florida, the experience of 772 patients listed for LT were retrospectively reviewed to study the impact of immediate mRECIST classification following locoregional therapy (LRT) on pre‐ and post‐LT outcomes. Patients who had progression of disease (PD; n = 72), failed to respond to LRT (n = 89) at any time point, or did not achieve radiologic complete response (CR; n = 224) were all at significant risk for wait‐list dropout (odds ratio [OR] = 12.11, 4.81, and 2.48; respectively). CR identified a cohort of patients who were at a reduced risk for wait‐list dropout. However, 24.9% eventually required further intervention while waiting for transplant, and as many as 82.4% were found to have residual HCC on explant pathology. Failure to respond to LRT was associated with increased risk for recurrence (OR = 3.00) more so than PD (OR = 1.36), suggesting that despite PD, patients who eventually can respond to LRT may represent favorable candidates for LT. In conclusion, for patients awaiting LT, the mRECIST assessment provides critical guidance for patient management. Although PD portends a poor prognosis, our findings suggest that further aggressive LRT should be pursued because a response to LRT may yield acceptable results for patients awaiting LT as well as after LT.
Superior Canal Dehiscence Involving the Superior Petrosal Sinus: A Novel Classification Scheme
Sweeney, Alex D. , O’Connell, Brendan P., Patel, Neil S. , Tombers, Nicole M. , Wanna, George B. , Lane, John I. , Carlson, Matthew L.

Mayo Clinic

Otology & Neurotology | September 10, 2018 | Volume: 39 | Issue: 9 | Pages: e849-e855

10.1097/mao.0000000000001965 | PMID 30199501 Get It

Objectives: To highlight superior semicircular canal dehiscence (SSCD) involving the superior petrosal sinus (SPS), and to propose a novel classification system for SPS associated SSCD with potential surgical implications. Study Design: Multicenter retrospective review. Setting: Three tertiary referral centers. Patients: All patients diagnosed with SPS associated SSCD (1/2000 to 8/2016). Radiographic findings and clinical symptoms were analyzed. Intervention: Surgical repair or observation. Main Outcome Measure: Radiographic findings and clinical symptoms were analyzed. Results: Thirty-three dehiscences (30 patients) involving the SPS were identified. The average age at the time of presentation was 52.5 years (median, 56.9; range, 4.9–75.3 yr), and 53.3% of patients were men. Three patients had bilateral SPS associated SSCD. The most common associated symptoms at presentation were episodic vertigo (63.6%), subjective hearing loss (60.6%), and aural fullness (57.6%). Four distinct types of dehiscence were identified: class Ia. SSCD involving a single dehiscence into an otherwise normal appearing SPS; class Ib. SSCD involving a single dehiscence into an apparent venous anomaly of the SPS; class IIa. SSCD involving two distinct dehiscences into the middle cranial fossa and the SPS; class IIb. SSCD involving a single confluent dehiscence into the middle cranial fossa and the SPS. Conclusions: SSCD involving the SPS represents a small but distinct subset of SSCD cases. This scenario can create a unique set of symptoms and surgical challenges when intervention is sought. Clinical findings and considerations for surgical intervention are provided to facilitate effective diagnosis and management.
Blood clotting and traumatic injury with shock mediates complement-dependent neutrophil priming for extracellular ROS, ROS-dependent organ injury and coagulopathy
Barrett, Christopher D. , Hsu, Albert, Ellson, Chris D., Miyazawa, Byron , Kong, Y-W, Greenwood, J D, Sperry, Jason L., Park, M S, Cohen, Mitchell J. , Zuckerbraun, Brian S. , Kong, Yi Wen , Kong, Y-W, Dhara, Sanjeev S. , Neal, Matthew D , Yaffe, Michael B.

Mayo Clinic

Clinical and Experimental Immunology | September 9, 2018 | Volume: 194 | Issue: 1 | Pages: 103-117

10.1111/cei.13166 | PMID 30260475 Get It

SummaryPolymorphonuclear (PMN) leucocytes participate in acute inflammatory pathologies such as acute respiratory distress syndrome (ARDS) following traumatic injury and shock, which also activates the coagulation system systemically. Trauma can prime the PMN nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex for an enhanced respiratory burst, but the relative role of various priming agents in this process remains incompletely understood. We therefore set out to identify mediators of PMN priming during coagulation and trauma-shock and determine whether PMN reactive oxygen species (ROS) generated in this manner could influence organ injury and coagulation. Initial experiments demonstrated that PMN are primed for predominantly extracellular ROS production by products of coagulation, which was abrogated by CD88/C5a receptor(C5aR) inhibition. The importance of this was highlighted further by demonstrating that known PMN priming agents result in fractionally different amounts of extracellular versus intracellular ROS release depending on the agent used. Plasma from trauma patients in haemodynamic shock (n = 10) also primed PMN for extracellular ROS in a C5a-dependent manner, which correlated with both complement alternative pathway activation and thrombin generation. Furthermore, PMN primed by preincubation with products of blood coagulation directly caused loss of endothelial barrier function in vitro that was abrogated by C5aR blockade or NADPH oxidase inhibition. Finally, we show in a murine model of trauma-shock that p47phox knock-out (KO) mice with PMN incapable of generating ROS were protected from inflammatory end-organ injury and activated protein C-mediated coagulopathy. In summary, we demonstrate that trauma-shock and coagulation primes PMN for predominantly extracellular ROS production in a C5a-dependent manner that contributes to endothelial barrier loss and organ injury, and potentially enhances traumatic coagulopathy.
Analysis of clinical outcomes of upper and lower extremity reconstructions in patients with soft‐tissue sarcoma
Kapoor, Trishul , Banuelos, Joseph, Adabi, Kian , Moran, Steven L. , Manrique, Oscar J.

Mayo Clinic

Journal of Surgical Oncology | September 9, 2018 | Volume: 118 | Issue: 4 | Pages: 614-620

10.1002/jso.25201 | PMID 30196551 Get It

Background and ObjectivesPrimary amputations have been the standard of treatment for extremity soft tissue sarcomas. However, over the last few decades, this mode of treatment has been increasingly replaced by limb‐sparing procedures.1 Our goal is to report the clinical outcomes of upper and lower extremity reconstructions in patients with a history of soft‐tissue sarcoma.MethodsA retrospective review of 178 patients with a history of soft‐tissue sarcoma who underwent upper or lower extremity reconstructions was conducted. Demographics, tumor characteristics, treatment modalities, type of flap utilized, functional outcomes, and postoperative donor‐/recipient‐site complications (DSC/RSC) were analyzed. Variables were compared between free and pedicle flaps (FF or PF).ResultsPF reconstructions had a higher rate of DSC (P < 0.044), whereas FF reconstructions had a higher rate of RSC (P < 0.03). Upper extremity reconstruction resulted in a mean QuickDASH score of 5.98 (SD 9.37) with no significant difference between PF and FF. Lower extremity reconstruction resulted in a mean score of 71.2 (SD 10.7) for PF and 71.3 (SD 5.1) for FF on the Lower Extremity Function Scale.ConclusionLimb‐preserving reconstruction with PF and FF is a reliable and safe option after sarcoma resection. In addition, long‐term outcomes are promising and reassure the adequate functionality of the limb.
Fabrication of a bilayer scaffold for small diameter vascular applications
Goins, Allison, Lichlyter, Darcy, Webb, Antonio R., Allen, Josephine B. , Ramaswamy, Vidhya, Ramaswamy, V.

Mayo Clinic

Journal of Biomedical Materials Research Part A | September 8, 2018 | Volume: 106 | Issue: 11 | Pages: 2850-2862

10.1002/jbm.a.36473 | PMID 30194900 Get It

AbstractOne of the greatest challenges plaguing cardiovascular tissue engineering has been the development of a compliant vascular graft. In this work, we report the development of a synthetic vascular graft with compliance similar to native arteries at physiological pressures. A bilayer scaffold was fabricated from a solid polymeric lumen made from poly(1,8 octanediol‐co‐citrate) (POC) and a microfibrous medial layer composed of type I collagen, elastin, and POC. Mechanical analysis revealed dynamic compliance, ~6.9% within 1% of native vessels, 5.9%. The burst pressure was an order of magnitude lower than native vessels (~400 mmHg vs. ~3000 mmHg) but was above physiological pressure ranges. Biocompatibility studies indicated the scaffold posed no acute cytotoxic risk to relevant cell types and supported the proliferation of vascular smooth muscle cells. In addition, upon exposure of the scaffold to whole blood, there was no statistically significant hemolysis, <2%. Overall this is a promising material system and scaffold to develop a biodegradable tissue‐engineered vascular graft. © 2018 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 106A: 2850–2862, 2018.
3D MR Elastography of Hepatocellular Carcinomas as a Potential Biomarker for Predicting Tumor Recurrence
Shan, Qungang , Yang, Hao , Kuang, Sichi , He, Bingjun , Zhang, Yao , Chen, Jingbiao , Zhang, Tianhui , Glaser, Kevin J. , Yin, Meng , Venkatesh, Sudhakar K. , Venkatesh, Sudhakar K , Yin, Meng , Wang, Jin , Liu, Yong , Zhu, Cairong , Chen, Jun , Ehman, Richard L.

Mayo Clinic

Journal of Magnetic Resonance Imaging | September 8, 2018 | Volume: 49 | Issue: 3 | Pages: 719-730

10.1002/jmri.26250 | PMID 30260529 Get It

BackgroundPreoperative prediction of tumor recurrence is important in the management of patients with hepatocellular carcinoma (HCC).PurposeTo investigate whether tumor stiffness derived by magnetic resonance elastography (MRE) could predict early recurrence of HCC after hepatic resection.Study TypeRetrospective.PopulationIn all, 99 patients with pathologically confirmed HCCs after surgical resection.Field Strength/Sequence3.0T; preoperative MRE with 60‐Hz mechanical vibrations using an active acoustic driver.AssessmentRegions of interest (ROIs) were manually drawn in the tumors to measure mean tumor stiffness. Surgical specimens were reviewed for histological grade, capsule, vascular invasion, and surgical margins. The early recurrence of HCC was defined as that occurring within 2 years after resection.Statistical TestsCox proportional hazard models were used to evaluate risk factors associated with the time to early recurrence.ResultsHCCs with recurrence had higher tumor stiffness, higher rate of advanced T stage, vascular invasion, lower rate of capsule formation, larger tumor size, higher aspartate aminotransferase (AST), and hepatitis B virus (HBV)‐DNA level and aspartate aminotransferase / alanine aminotransferase ratio (P = 0.031, 0.007, 0.01, <0.001, 0.015, 0.034, 0.01, and 0.014, respectively) than HCCs without recurrence. Vascular invasion (hazard ratio [HR] = 2.922; 95% confidence interval [CI]: [1.079, 7.914], P = 0.035) and mean tumor stiffness (HR = 1.163; 95% CI: [1.055, 1.282], P = 0.002) were risk factors associated with early recurrence. Each 1‐kPa increase in tumor stiffness was associated with a 16.3% increase in the risk for tumor recurrence.Data ConclusionThe mean stiffness of HCCs may be a useful, noninvasive, quantitative biomarker for the prediction of early HCC recurrence after hepatic resection.Level of Evidence: 4Technical Efficacy: Stage 5J. Magn. Reson. Imaging 2019;49:719–730.
The Value of Unique Device Identifiers in Plastic Surgery
Aston, Jeffrey W., Howarth, Ashley L. , Wilson, Natalia , Mahabir, Raman C.

Mayo Clinic

Aesthetic Surgery Journal | September 8, 2018 | Volume: 38 | Issue: 11 | Pages: 1264-1266

10.1093/asj/sjy210 | PMID 30202871 Get It

Utility and prognostic value of 18F‐FDG positron emission tomography‐computed tomography scans in patients with newly diagnosed multiple myeloma
Aljama, Mohammed A. , Sidiqi, M Hasib , Lacy, Martha Q. , Gertz, Morie A. , Dingli, David , Muchtar, Eli , Fonder, Amie , Hayman, Suzanne R. , Hobbs, Miriam, Warsame, Rahma , Kourelis, Taxiarchis , Hwa, Yi L. , Kapoor, Prashant , Kyle, Robert A. , Kumar, Shaji , Buadi, Francis K. , Gertz, Morie A , Fonder, Amie L, Gonsalves, Wilson , Warsame, Rahma , Kourelis, Taxiarchis , Hwa, Yi Lisa, Leung, Nelson , Go, Ronald S , Rajkumar, S Vincent , Muchtar, E , Sidiqi, M Hasib , Dingli, David , Dispenzieri, Angela , Gonsalves, Wilson I. , Leung, Nelson , Go, Ronald S. , Rajkumar, S. Vincent

Mayo Clinic

American Journal of Hematology | September 8, 2018 | Volume: 93 | Issue: 12 | Pages: 1518-1523

10.1002/ajh.25279 | PMID 30194770 Get It

AbstractPositron emission tomography‐computed tomography (PET‐CT) can identify bony lesions, assess disease burden, and detect extramedullary disease (EMD) in patients with multiple myeloma. We retrospectively reviewed records of patients who underwent PET‐CT within 60 days of a new diagnosis (before therapy commenced) to identify the nature and prognostic impact of PET‐CT abnormalities. Patients (N = 313) were seen from April 2005 through June 2017. Of the 234 patients (75%) with focal lesions (FLs), 182 (58%) had at least 3 FLs, 38 (12%) had EMD, and 204 (65%) had documented myelomatous lytic lesions. The median maximum standardized uptake value (SUVmax) for the entire cohort was 5.9 (range 1.5‐48.3). Presence of at least 3 FLs and EMD predicted inferior overall survival (OS); median OS was 57.8 months for patients with 3 or more FLs and 103.6 months for patients with fewer than 3 FLs (P = .003). The median OS was 45.5 and 71.8 months for patients with and without EMD, respectively (P = .004). No clear SUVmax cutoff was predictive of progression‐free survival or OS. PET‐CT is a valuable tool for assessing disease burden and could provide prognostic information about a contemporary cohort of patients with newly diagnosed myeloma who received treatment with novel agents.
Adventitial cysts of the radial artery are joint connected
Lewallen, Laura, Spinner, Robert J. , Amrami, Kimberly K. , Lewallen, Laura W, Kakar, Sanjeev

Mayo Clinic

Clinical Anatomy | September 8, 2018 | Volume: 32 | Issue: 2 | Pages: 201-205

10.1002/ca.23271 | PMID 30194877 Get It

Volar radial wrist masses are common. Adventitial cysts of the radial artery are rarely reported and poorly understood. We describe a case series of adventitial cysts in association with the radial artery and detail their pathophysiology and treatment. We conducted an Institutional Review Board‐approved retrospective review of patients treated at our institution from 1997 to 2018. Twelve patients were identified. Presenting symptoms typically included pain and swelling over the volar radial wrist. High‐resolution magnetic resonance imaging (MRI) demonstrated tubular, cystic lesions within the adventitia of the radial artery with connections to the wrist joint confirmed on multiplanar imaging: (radiocarpal joint = 10; scaphotrapeziotrapezoidal joint = 1; and intercarpal joint = 1). Seven patients underwent operation, at which time the cyst was resected and the articular branch disconnected. These patients reported resolution of their symptoms without clinical recurrence. The consistent finding of a joint connection in these cases of adventitial cysts associated with the radial artery has important clinical implications. The joint connection needs to be disconnected. Level of evidence: Level IV, case series. Clin. Anat. 32:201–205, 2019. © 2018 Wiley Periodicals, Inc.